Join the Exalgo group to help and get support from people like you.
Exalgo News
1 in 10 ICU Patients With Heart Issues Has Illicit Drugs in Their System
FRIDAY, Aug. 18, 2023 – More than 1 out of every 10 patients who land in an ICU with a potentially deadly heart emergency test positive for recreational drug use, a new French study reports. About...
Prevalence of Recreational Drug Use 11 Percent in Cardiac ICUs
FRIDAY, Aug. 18, 2023 – For patients hospitalized in intensive cardiac care units (ICCUs), the prevalence of recreational drug use is 11 percent, according to a study published online Aug. 15 in...
Most People Initiating Opioid Rx Have Very Low Use Trajectory
MONDAY, Aug. 14, 2023 – Most adults initiating treatment with prescription opioids have relatively low and time-limited exposure to opioids during a five-year period, according to a study published...
FDA Medwatch Alert: Drug Safety Communication: All Opioid Pain Medicines - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use
ISSUE: The FDA is requiring several updates to the prescribing information for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medicines. This includes stating for a...
FDA Medwatch Alert: PharMEDium Services, LLC Issues Voluntary Nationwide Recall of 0.5 mg/mL HYDROmorphone HCl in 0.9% Sodium Chloride 1 mL in 3 mL BD Syringe Due to Presence of Sulfite
June 28, 2019 – PharMEDium Services, LLC is voluntarily recalling 45 lots of 0.5 mg/mL HYDROmorphone HCl in 0.9% Sodium Chloride 1 mL in 3 mL BD Syringe to the user level. The product is being...
FDA Medwatch Alert: Implanted Pumps: Safety Communication - Use Caution When Selecting Pain Medicine for Intrathecal Administration
ISSUE: The FDA is aware that patients undergoing treatment or management of pain are commonly given pain medicines in the spinal fluid (intrathecal administration) that are not FDA approved for use...
FDA Medwatch Alert: Hydromorphone HCL Injection USP by Hospira: Recall - Potential For Empty Or Cracked Glass Vials
ISSUE: Hospira is voluntarily recalling three lots of Hydromorphone HCl Injection, USP CII 10 mg/mL, 1 mL in 2 mL Single Dose Vials lot numbers 71330DD (NDC 0409-2634-01), and 691853F and 700753F...
FDA Medwatch Alert: Injectable Products by SCA Pharmaceuticals: Recall - Potential Contamination
ISSUE: SCA Pharmaceuticals LLC (“SCA Pharmaceuticals”) is voluntarily recalling various lots of injectable products to the hospital level. There is a potential for the products to contain microbial co...
FDA Medwatch Alert: Hydromorphone HCl Injection, USP 2 mg/mL, and Levophed (Norepinephrine Bitartrate Injection, USP) 4 mg/4 mL (1 mg/mL) Vial by Hospira: Recall - Lack of Sterility Assurance
ISSUE: Hospira is voluntarily recalling one lot of Hydromorphone HCI Injection, USP, CII 2 mg/mL and four lots of Levophed (Norepinephrine Bitartrate Injection, USP), 4 mg/4 mL (1 mg/mL) Vial due to...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications
ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...
FDA Approves Mallinckrodt's Exalgo (hydromorphone HCl) Extended-Release Tablets 32 mg (CII) for Opioid-Tolerant Patients with Moderate-to-Severe Chronic Pain
ST. LOUIS--(BUSINESS WIRE)--Aug 27, 2012 - The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet...
FDA Medwatch Alert: Hospira Hydromorphone Hydrochloride Injection 2 MG/ML, 1 mL fill in 2.5 mL Carpuject: Recall- May Contain More Than The Intended Fill Volume
Issue: Hospira and FDA notified healthcare professional of a nationwide voluntraty recall of one lot of Hydromorphone Injection, USP, 2 mg/mL, (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1312-30,...
FDA Medwatch Alert: Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject: Recall - May Contain More Than the Intended Fill Volume
ISSUE: Hospira, Inc. notified healthcare professionals of a recall of one lot of Hydromorphone Hydrochloride Injection 1 MG/ML, due to reports of a single Carpuject containing more than the 1 mL...
Ask a question
To post your own question to this support group, sign in or create an account.